TJ102 / Phrontline Biopharma - LARVOL DELTA

A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: Phrontline Biopharma

First-in-human • New P1/2 trial • Platinum resistant • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

TJ102: A promising bispecific dual-payload ADC targeting CDH6 and folate receptor alpha (FRα) for the treatment of ovarian and kidney cancers (AACR 2025) - "Altogether, these findings highlight TJ102 as a promising bispecific dual-payload ADC with highly potent anti-tumor efficacy and a favorable safety profile in ovarian and kidney cancers. Its dual-targeting approach not only increases the therapeutic index but also mitigates potential tumor resistance that may arise during future clinical applications."

ADC • Bispecific • Late-breaking abstract • Breast Cancer • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • CDH6 • FOLR1